---
schema_version: "secwatch.filing_event.v1"
accession: "0001062822-24-000023"
form_type: "8-K"
ticker: "LXRX"
cik: "0001062822"
company_name: "LEXICON PHARMACEUTICALS, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:51:06.519860+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lexicon Q1 net loss $48.4M; INPEFA sales $1.1M, up 63% QoQ

## Summary
- Net loss of $48.4M ($0.20 per share) vs $31.9M ($0.17) in Q1 2023; SG&A jumped to $32.1M on launch spending.
- Revenue of $1.1M from INPEFA (sotagliflozin) heart failure launch; market access ~40%, expansion expected H2 2024.
- Cash and investments $355.6M as of March 31, up from $170M due to convertible preferred stock issuance in March.
- NDA resubmission for ZYNQUISTA in type 1 diabetes with CKD expected mid-2024; Phase 3 for HCM to start mid-2024.
- Enrollment on track for Phase 2b PROGRESS study of LX9211 in DPNP; topline data expected Q2 2025.

## SEC filing metadata
- accession: 0001062822-24-000023
- form_type: 8-K
- ticker: LXRX
- cik: 0001062822
- company_name: LEXICON PHARMACEUTICALS, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000023/0001062822-24-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000023/lxrx-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062822-24-000023
- JSON: https://secwatch.observer/filing/0001062822-24-000023.json
- Plain text: https://secwatch.observer/filing/0001062822-24-000023.txt

## Key facts
- Earnings Releases
  LEXICON PHARMACEUTICALS, INC. reported three months ended March 31, 2024 results: revenue $1.1 million, net income $48.4 million, or $0.20 per share.
  - Period: three months ended March 31, 2024
  - Revenue: $1.1 million
  - Net income: $48.4 million, or $0.20 per share
  - Result: reported results
  source text: continues to progress, with favorable feedback from healthcare providers and ongoing negotiations with payers regarding expanded market access. Net sales for the quarter were $1.1 million reflecting 63 percent growth from the previous quarter. Market access remains at approximately 40% overall and is expected to expand in the second half of 2024. ZYNQUISTA
  evidence_url: https://www.sec.gov/Archives/edgar/data/1062822/000106282224000023/0001062822-24-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.